

November 10, 2014



Aethlon Medical Announces Presentation of Ebola Treatment Data This Friday, November 14th at the ASN Annual Meeting

SAN DIEGO, Nov. 10, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, announced today that treatment data resulting from the administration of Hemopurifier® therapy to a patient infected with Ebola virus will be presented this Friday, November 14th at the American Society of Nephrology (ASN) Annual Meeting.



The treatment data will be presented during an ASN Special Session on Ebola and Dialysis by Professor Helmut Geiger M.D., Chief of Nephrology at Goethe University, Frankfurt University Hospital, where the patient was treated. The data will include the results of patient viral load measurements taken before and after Hemopurifier® administration. Additionally, the quantification of ebola viruses captured within the Hemopurifier® during treatment will be reported. On November 5th, officials at Frankfurt University Hospital disclosed that the treated patient, who was suffering from multiple organ failure, was no longer infected with ebola virus and is expected to make a full recovery.

The ASN Annual Meeting is the world's premier nephrology conference with more than 13,000 medical professionals from across the globe attending this years gathering at the Pennsylvania Convention Center in Philadelphia.

The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. At present, no antiviral therapy or vaccine has proven to be effective

against Ebola virus infection in humans. According to the World Health Organization (WHO), more than 5,000 deaths have been attributed to the current ebola virus epidemic. The patient at Frankfurt University Hospital was administered Hemopurifier® therapy through special approval from The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM), an independent federal higher authority within the portfolio of the Federal Ministry of Health of Germany.

In the care of ebola-infected individuals, the Hemopurifier targets two unmet medical needs: the rapid elimination of circulating viruses to inhibit continued progeny virus replication and the direct targeting of secreted glycoproteins that overwhelm the host immune response.

The broad-spectrum antiviral and immunotherapeutic device is deployed for use within the global infrastructure of dialysis and CRRT machines already located in hospitals and clinics.

Aethlon is also preparing to initiate the first U.S. clinical studies of Hemopurifier therapy based on the United States Food and Drug Administration's (FDA) approval of an Investigational Device Exemption (IDE) that was previously submitted by the Company. The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).

To date, Hemopurifier therapy has been successfully administered in approximately one hundred treatment experiences in health compromised HIV and HCV infected individuals. These studies were conducted at the Apollo Hospital, Fortis Hospital, Sigma New Life Hospital, and the Medanta Medicity Institute, all located in India. *In vitro* validation studies that demonstrated the ability of the Hemopurifier to capture Zaire and other strains of ebola virus have been conducted by researchers at the United States Army Medical Research Institute for Infectious Diseases (USAMRIID) and the United States Centers for Disease Control and Prevention (CDC).

In vitro studies conducted by leading government and non-government research organizations have also validated that the Hemopurifier® captures a broad-spectrum of bioterror and pandemic threats. Like ebola virus, many of these threats are not addressed with an effective drug or vaccine. Viruses validated to be captured by the Hemopurifier® include; dengue hemorrhagic virus, lassa hemorrhagic virus, H5N1 avian influenza (bird flu), the reconstructed 1918 influenza virus (r1918), 2009 H1N1 influenza virus (swine flu), West Nile virus, and monkeypox, which serves as a model for human smallpox infection.

In oncology, the Hemopurifier® has been validated to capture tumor-secreted exosomes, which suppress the immune response and contribute to the spread of metastasis in cancer patients. In both oncology and infectious disease indications, the Hemopurifier® can be combined with standard of care therapies as an adjunct strategy to improve patient benefit.

About Aethlon Medical, Inc.

Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier®, a first-in-class antiviral and immunotherapeutic device that selectively targets the broad-spectrum elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and

neurological disorders. For more information, please visit <http://www.aethlonmedical.com/> and connect with the Company on [Twitter](#), [LinkedIn](#), [Facebook](#) and [Google+](#).

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

James A. Joyce
Chairman and CEO
(Office) 858.459.7800 x301
(Cell) 619-368-2000
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

Photo - <https://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b>

SOURCE Aethlon Medical, Inc.